Appili Therapeutics Inc. APLI.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 263.33% | 145.00% | 66.70% | -60.38% | -88.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 263.33% | 145.00% | 66.70% | -60.38% | -88.23% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 263.33% | 145.00% | 66.70% | -60.38% | -88.23% |
| SG&A Expenses | 5.53% | -12.87% | -11.41% | -10.72% | -12.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.65% | -33.16% | -38.55% | -27.68% | -7.24% |
| Operating Income | 25.88% | 34.93% | 39.84% | 26.03% | -0.57% |
| Income Before Tax | -104.10% | -56.47% | 28.55% | 32.22% | 41.29% |
| Income Tax Expenses | 90.68% | 545.80% | 18,400.00% | 399.17% | -16.51% |
| Earnings from Continuing Operations | -103.83% | -59.82% | 26.00% | 30.26% | 40.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.83% | -59.82% | 26.00% | 30.26% | 40.93% |
| EBIT | 25.88% | 34.93% | 39.84% | 26.03% | -0.57% |
| EBITDA | 25.86% | 34.94% | 39.88% | 26.07% | -0.57% |
| EPS Basic | -100.73% | -61.01% | 27.62% | 30.41% | 40.95% |
| Normalized Basic EPS | -101.19% | -57.58% | 30.00% | 32.35% | 41.67% |
| EPS Diluted | -100.73% | -61.01% | 27.62% | 30.41% | 40.95% |
| Normalized Diluted EPS | -101.19% | -57.58% | 30.00% | 32.35% | 41.67% |
| Average Basic Shares Outstanding | 1.38% | -0.90% | 1.46% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 1.38% | -0.90% | 1.46% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |